In the News |
October 28, 2024
Backed by Novo, Kivu debuts with $92M to build ‘kinder, gentler’ medicines

“Kivu’s two-part goal is simple: achieve the highest ADC concentration possible within the tumour microenvironment, while minimising dose reductions and treatment interruptions.”

Elizabeth S. Eaton, FirstWord Pharma